Ratings for Marinus Pharma (NASDAQ:MRNS) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.71, a high estimate of $28.00, and a low estimate of $3.00. Marking an increase of 25.52%, the current average surpasses the previous average price target of $16.50.

Exploring Analyst Ratings: An In-Depth Overview

The perception of Marinus Pharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Marinus Pharma's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Marinus Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Marinus Pharma: A Closer Look

Unraveling the Financial Story of Marinus Pharma

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Marinus Pharma's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 0.39%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Marinus Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -580.93% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Marinus Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -117.16%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -22.47%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.4, caution is advised due to increased financial risk.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.